Latest News From Lumira Ventures

Bardy Diagnostics™ Receives 510(k) Clearance from U.S. FDA for its 14-Day CAM™ patch

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

SEATTLE, Sept. 6, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the 14-Day version of the Carnation Ambulatory Monitor …

Satsuma Pharmaceuticals Inc. Proposes Initial Public Offering of Common Stock

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma”), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that it has commenced an underwritten initial public offering of …

Bardy Diagnostics™ Selected As 1 of 6 Disruptive MedTech Startups for the HealthTech Arkansas Accelerator Program

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

SEATTLE, Aug. 9, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that HealthTech Arkansas, a healthcare accelerator and investment fund that connects early-stage healthcare companies with disruptive technologies to Arkansas healthcare providers, has …

FDA Grants G1 Therapeutics Breakthrough Therapy Designation in Q2 2019 Corporate and Financial Update

Jennifer Schram G1 Therapeutics, Main Page, Portfolio News, Press Release

Related Article: G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2019. …

Aurinia Releases Q2 2019 Financial Results

Jennifer Schram Aurinia Pharmaceuticals, Main Page, Portfolio News, Press Release

Related Article: Aurinia Reports First Quarter 2019 Financial Results & Recent Operational Highlights Review condensed consolidated financials here: https://ir.auriniapharma.com/press-releases/detail/153 VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused …

Endotronix Receives conditional IDE approval from the US Food & Drug Administration

Jennifer Schram Endotronix, Main Page, Portfolio News, Press Release

Related Article: Endotronix Receives 13485:2016 certification from the British Standards Institution (BSI) for its Quality Management System LISLE, Ill., Aug. 1, 2019 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced …